Fight against Covid-19: Here is a list of vaccines approved in India

Besides Bharat Biotech's nasal vaccine, India has 13 vaccines to fight against Covid-19. Two have been approved for manufacturing, while 11 have been approved for emergency use

vaccine
Representational image
BS Web Team New Delhi
3 min read Last Updated : Sep 06 2022 | 5:16 PM IST
With the approval of Bharat Biotech's ChAd36-SARS-CoV-S Covid-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine, India has added one more vaccine in the fight against the Covid pandemic. Health minister Mansukh Mandaviya, on Tuesday, took to Twitter to make the announcement.

However, besides the latest nasal vaccine, India already has 13 vaccines for the fight against Covid-19. Two have been approved for manufacturing and sale in the country. Eleven have been approved for emergency use.

Which Covid-19 vaccines are available in India?

Covishield

Developed by the Serum Institute of India, the vaccine was approved for use on January 1, 2022, according to the ICMR website. It has a shelf life of 9 months.

It has the same formulation as the AstraZeneca vaccine (AZD1222) developed by Oxford University.

Covaxin (2 vaccines)

Developed by Bharat Biotech, the whole-virion inactivated SARS-CoV-2 vaccine got approval for use on January 27, 2022. It has a shelf life of 12 months.

It has also been approved for usage in 13 other countries, including neighbouring Iran and Nepal, besides Malaysia, Mauritius, Nepal, and the Philippines.

It is fully approved for people above the age of 18. However, for people between the age of 12 and 18, it is approved for emergency use. 

Sputnik-V (Emergency Use, 3 vaccines)

Developed by Russia's Gamaleya, Sputnik-V was approved for emergency use in India on April 12, 2021. It is imported by Dr Reddy's Lab Ltd.

Another vaccine under the name, developed by Panacea Biotec Ltd, has also received DGCA's approval for emergency use.

Another vaccine under the same name has also been manufactured by Hetero Biopharma Ltd in India. It received emergency use approval on October 7, 2021.

Sputnik Light (Emergency Use)

It was also developed by Gamaleya and got approval on February 2, 2022. In India, it is imported by Dr Reddy's Lab Ltd.

Spikevax (Emergency Use)

Developed by Moderna, it is imported into India by Cipla Ltd. It was approved in India on June 29, 2021.

Jcovden (Emergency Use)

It was developed by Janssen and received approval on August 7, 2021. In India, it is developed by Biological E.

Gemcovac-19 (Emergency Use)

Developed by Gennova Biopharmaceuticals Ltd, this vaccine has been approved in India only.

ZyCoV-D (Emergency Use)

It was developed by Cadilla Healthcare Ltd and got approval for emergency use on August 10, 2021. It has been approved to be used for people above 12 years of age.

Corbevax (Emergency Use)

Developed by Biological E Ltd, the vaccine was approved for emergency use on December 28, 2021. It has received approvals in Botswana and India.

Covovax (Emergency Use)

Developed by the Serum Institute of India, Covovax has the same formulation as Novavax used in the US. It received emergency use approval on December 28, 2021.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBharat BiotechSerum Institute of IndiaMansukh Lal Mandaviyanasal vaccinecoronaVaccineAstraZenecaDGCACipla

Next Story